Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

Can the GSK share price soar higher after hitting 17-year high?

The British drug maker wowed investors last month after upgrading its full-year earnings guidance following a strong third quarter performance that sent shares soaring, with analysts believing the stock could climb even higher.

GlaxoSmithKline (GSK) saw its share price close to a 17-year high of £17.82 in the wake of its third quarter (Q3) results last month, with the drug maker recording strong sales growth, prompting it to upgrade its full-year earnings forecast.

GSK now expects earnings per share (EPS) to be ‘around flat’ year-on-year, representing an upgrade from its previous guidance that forecast EPS would decline by between 3% and 5% in 2019.

‘GSK has made further good progress in Q3, with sales growth across all three businesses, and we have today upgraded our full-year EPS guidance,’ GSK CEO Emma Walmsley said.

‘This quarter we have continued to strengthen our pipeline and have advanced assets in Respiratory, HIV and, notably, Oncology, where we are on track to file three innovative medicines by year end, following positive pivotal trial data.’

Looking to trade GSK and other pharmaceutical stocks? Open a live or demo account with IG.

Analysts believe GSK shares could see further gains

After its shares hit a 17-year high last month, GSK’s stock has fallen some 3% to trade at £17.11 levels as of 16:15 GMT on Monday.

But analysts remain upbeat about the prospect of the stock not only returning to record levels but breaking above them.

Analysts at DZ Bank remain the most optimistic, reiterating their ‘buy’ rating for the stock in October and issuing a target price £20 a share. Liberum Capital and Credit Suisse gave a price target of £18.90 and £18 respectively.

Based on the stock’s current price, the three banks believe that GSK’s share price has a potential upside of between 5.2% to 16.8%.

However, Barclays Capital reiterated it ‘equal weight’ rating for the stock, but issued a target price of £16.50, representing a potential downside for the share price of 3.5%

GSK will unveil its fourth quarter results on February 5.

You can go long or short GSK with IG using derivatives like CFDs and spread bets.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Act on share opportunities today

Go long or short on thousands of international stocks with spread bets and CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take advantage while conditions prevail.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Sunday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.


For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.